NSE filing, NSE: TIRUMALCHM. Summary written from the filing by ALFA Finder's alert engine.
Thirumalai Chemicals Ltd: key numbers
- Share price
- ₹116.85
- Market cap
- ₹1,409 Cr
- Revenue (annual)
- ₹1,736 Cr
- Net profit (annual)
- ₹-167.9 Cr
- P/E (TTM)
- -9.3×Sector 34.1×
- Promoter holding
- 37.13%+0.00% QoQ
- FII holding
- 1.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thirumalai Chemicals Ltd
All →Thirumalai Chemicals Promoter Reclassification
Thirumalai Chemicals received requests from two promoter group members, Narayan Santhanam and Deepa Ajay, to reclassify 100,000 shares (0.08%) as public. The board will consider the requests at its next meeting.
Thirumalai Chemicals Legal & Regulatory
Thirumalai Chemicals received a customs audit observation demanding Rs. 0.2452 Crore for alleged ineligible export benefits. The company contests the demand as erroneous and insignificant.
- Value
- ₹0.25 Cr
- From
- Assistant Commissioner, Office of Commissioner of Customs Audit Chennai
Thirumalai Chemicals Other Announcement
The company has filed its quarterly shareholding pattern under Regulation 31 for the period ended September 30, 2026.
Thirumalai Chemicals Legal & Regulatory
Thirumalai Chemicals received a tax show cause notice for Rs. 17.31 Crore regarding GST discrepancies for FY 2023-24. The company intends to contest the demand.
- Value
- ₹17.31 Cr
Thirumalai Chemicals Merger & Restructuring
Thirumalai Chemicals Limited sold 9,50,000 equity shares in Ultramarine & Pigments Limited through the open market. This transaction reduced its holding from 9.38% to 6.13%.
Thirumalai Chemicals Legal & Regulatory
Thirumalai Chemicals received a GST show cause notice regarding tax scrutiny for FY 2022-2023. The total demand amount is Rs. 13.52 Lakhs.
- Value
- ₹0.14 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr